Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
New drug shows promise against treatment-resistant non-small cell lung cancer

New drug shows promise against treatment-resistant non-small cell lung cancer

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New database allows researchers to match old drugs for new diseases

New database allows researchers to match old drugs for new diseases

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

New era of lung cancer therapy close to dawning

New era of lung cancer therapy close to dawning

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Lung cancer patients with Del19 mutation benefit most from afatinib

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Novel multi-kinase inhibitor shows early promise in NSCLC

Novel multi-kinase inhibitor shows early promise in NSCLC

New method to monitor activity of gene promoters during response to drug

New method to monitor activity of gene promoters during response to drug

Icotinib matches gefitinib in NSCLC second or third line

Icotinib matches gefitinib in NSCLC second or third line